These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 30734775)

  • 1. Biomaterials as vectors for the delivery of CRISPR-Cas9.
    Eoh J; Gu L
    Biomater Sci; 2019 Mar; 7(4):1240-1261. PubMed ID: 30734775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.
    Wang HX; Li M; Lee CM; Chakraborty S; Kim HW; Bao G; Leong KW
    Chem Rev; 2017 Aug; 117(15):9874-9906. PubMed ID: 28640612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multifunctional AAV-CRISPR-Cas9 and its host response.
    Chew WL; Tabebordbar M; Cheng JK; Mali P; Wu EY; Ng AH; Zhu K; Wagers AJ; Church GM
    Nat Methods; 2016 Oct; 13(10):868-74. PubMed ID: 27595405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different Methods of Delivering CRISPR/Cas9 Into Cells.
    Chandrasekaran AP; Song M; Kim KS; Ramakrishna S
    Prog Mol Biol Transl Sci; 2018; 159():157-176. PubMed ID: 30340786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomaterial-Based CRISPR/Cas9 Delivery Systems for Tumor Treatment.
    Li M; Chen F; Yang Q; Tang Q; Xiao Z; Tong X; Zhang Y; Lei L; Li S
    Biomater Res; 2024; 28():0023. PubMed ID: 38694229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications.
    Liu C; Zhang L; Liu H; Cheng K
    J Control Release; 2017 Nov; 266():17-26. PubMed ID: 28911805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR-Cas9 gene editing: Delivery aspects and therapeutic potential.
    Oude Blenke E; Evers MJ; Mastrobattista E; van der Oost J
    J Control Release; 2016 Dec; 244(Pt B):139-148. PubMed ID: 27498021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR/Cas9 delivery with one single adenoviral vector devoid of all viral genes.
    Ehrke-Schulz E; Schiwon M; Leitner T; Dávid S; Bergmann T; Liu J; Ehrhardt A
    Sci Rep; 2017 Dec; 7(1):17113. PubMed ID: 29215041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The CRISPR/Cas9 system: Their delivery, in vivo and ex vivo applications and clinical development by startups.
    Song M
    Biotechnol Prog; 2017 Jul; 33(4):1035-1045. PubMed ID: 28440027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies for nonviral nanoparticle-based delivery of CRISPR/Cas9 therapeutics.
    Chen F; Alphonse M; Liu Q
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 May; 12(3):e1609. PubMed ID: 31797562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges.
    Mout R; Ray M; Lee YW; Scaletti F; Rotello VM
    Bioconjug Chem; 2017 Apr; 28(4):880-884. PubMed ID: 28263568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Key considerations in designing CRISPR/Cas9-carrying nanoparticles for therapeutic genome editing.
    Xu Y; Liu R; Dai Z
    Nanoscale; 2020 Oct; 12(41):21001-21014. PubMed ID: 33078813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct Cytosolic Delivery of CRISPR/Cas9-Ribonucleoprotein for Efficient Gene Editing.
    Mout R; Ray M; Yesilbag Tonga G; Lee YW; Tay T; Sasaki K; Rotello VM
    ACS Nano; 2017 Mar; 11(3):2452-2458. PubMed ID: 28129503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress of delivery methods for CRISPR-Cas9.
    Yang W; Yan J; Zhuang P; Ding T; Chen Y; Zhang Y; Zhang H; Cui W
    Expert Opin Drug Deliv; 2022 Aug; 19(8):913-926. PubMed ID: 35818792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomaterial-assisted targeted and controlled delivery of CRISPR/Cas9 for precise gene editing.
    Iqbal Z; Rehman K; Xia J; Shabbir M; Zaman M; Liang Y; Duan L
    Biomater Sci; 2023 May; 11(11):3762-3783. PubMed ID: 37102700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges in CRISPR/CAS9 Delivery: Potential Roles of Nonviral Vectors.
    Li L; He ZY; Wei XW; Gao GP; Wei YQ
    Hum Gene Ther; 2015 Jul; 26(7):452-62. PubMed ID: 26176432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cationic Polymer-Mediated CRISPR/Cas9 Plasmid Delivery for Genome Editing.
    Zhang Z; Wan T; Chen Y; Chen Y; Sun H; Cao T; Songyang Z; Tang G; Wu C; Ping Y; Xu FJ; Huang J
    Macromol Rapid Commun; 2019 Mar; 40(5):e1800068. PubMed ID: 29708298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid-Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Components.
    Kazemian P; Yu SY; Thomson SB; Birkenshaw A; Leavitt BR; Ross CJD
    Mol Pharm; 2022 Jun; 19(6):1669-1686. PubMed ID: 35594500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Vivo Ovarian Cancer Gene Therapy Using CRISPR-Cas9.
    He ZY; Zhang YG; Yang YH; Ma CC; Wang P; Du W; Li L; Xiang R; Song XR; Zhao X; Yao SH; Wei YQ
    Hum Gene Ther; 2018 Feb; 29(2):223-233. PubMed ID: 29338433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR/Cas9; A robust technology for producing genetically engineered plants.
    Farooq R; Hussain K; Nazir S; Javed MR; Masood N
    Cell Mol Biol (Noisy-le-grand); 2018 Nov; 64(14):31-38. PubMed ID: 30511631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.